JP2020528888A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528888A5 JP2020528888A5 JP2020502672A JP2020502672A JP2020528888A5 JP 2020528888 A5 JP2020528888 A5 JP 2020528888A5 JP 2020502672 A JP2020502672 A JP 2020502672A JP 2020502672 A JP2020502672 A JP 2020502672A JP 2020528888 A5 JP2020528888 A5 JP 2020528888A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- iron
- salt
- iii
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 26
- 229930006000 Sucrose Natural products 0.000 claims 9
- 239000005720 sucrose Substances 0.000 claims 9
- 235000010445 lecithin Nutrition 0.000 claims 8
- 239000000787 lecithin Substances 0.000 claims 8
- -1 sucrose fatty acid ester Chemical class 0.000 claims 8
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 5
- 229920000881 Modified starch Polymers 0.000 claims 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims 5
- 239000000194 fatty acid Substances 0.000 claims 5
- 229930195729 fatty acid Natural products 0.000 claims 5
- 229940067606 lecithin Drugs 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000001959 sucrose esters of fatty acids Substances 0.000 claims 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 4
- 239000000654 additive Substances 0.000 claims 4
- 159000000003 magnesium salts Chemical class 0.000 claims 4
- 208000005475 Vascular calcification Diseases 0.000 claims 3
- 229910052742 iron Inorganic materials 0.000 claims 3
- 239000001095 magnesium carbonate Substances 0.000 claims 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 3
- 229930003231 vitamin Natural products 0.000 claims 3
- 229940088594 vitamin Drugs 0.000 claims 3
- 239000011782 vitamin Substances 0.000 claims 3
- 235000013343 vitamin Nutrition 0.000 claims 3
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 206010002906 aortic stenosis Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 2
- 239000000395 magnesium oxide Substances 0.000 claims 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical group [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 206010065558 Aortic arteriosclerosis Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930003448 Vitamin K Natural products 0.000 claims 1
- 201000001962 aortic atherosclerosis Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 235000019168 vitamin K Nutrition 0.000 claims 1
- 239000011712 vitamin K Substances 0.000 claims 1
- 150000003721 vitamin K derivatives Chemical group 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 229940046010 vitamin k Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023076299A JP2023090869A (ja) | 2017-07-26 | 2023-05-02 | 心血管器官の病態の予防及び処置における使用のための組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102017000085412 | 2017-07-26 | ||
| IT102017000085412A IT201700085412A1 (it) | 2017-07-26 | 2017-07-26 | Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare |
| PCT/IB2018/055586 WO2019021232A1 (en) | 2017-07-26 | 2018-07-26 | Composition for use in the prevention and treatment of pathologies of the cardiovascular apparatus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076299A Division JP2023090869A (ja) | 2017-07-26 | 2023-05-02 | 心血管器官の病態の予防及び処置における使用のための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020528888A JP2020528888A (ja) | 2020-10-01 |
| JP2020528888A5 true JP2020528888A5 (enExample) | 2021-09-02 |
Family
ID=60451085
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502672A Pending JP2020528888A (ja) | 2017-07-26 | 2018-07-26 | 心血管器官の病態の予防及び処置における使用のための組成物 |
| JP2023076299A Pending JP2023090869A (ja) | 2017-07-26 | 2023-05-02 | 心血管器官の病態の予防及び処置における使用のための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076299A Pending JP2023090869A (ja) | 2017-07-26 | 2023-05-02 | 心血管器官の病態の予防及び処置における使用のための組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20200206157A1 (enExample) |
| EP (1) | EP3657963A1 (enExample) |
| JP (2) | JP2020528888A (enExample) |
| KR (1) | KR20200032691A (enExample) |
| CN (1) | CN111031813A (enExample) |
| BR (1) | BR112020000902B1 (enExample) |
| CA (1) | CA3070659A1 (enExample) |
| CL (1) | CL2020000170A1 (enExample) |
| CO (1) | CO2020000526A2 (enExample) |
| EA (1) | EA202090069A1 (enExample) |
| IL (1) | IL272138B2 (enExample) |
| IT (1) | IT201700085412A1 (enExample) |
| JO (1) | JOP20200012A1 (enExample) |
| MA (1) | MA49794A (enExample) |
| MX (1) | MX2020000806A (enExample) |
| PE (1) | PE20200794A1 (enExample) |
| PH (1) | PH12020550031A1 (enExample) |
| WO (1) | WO2019021232A1 (enExample) |
| ZA (1) | ZA202000461B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201700089258A1 (it) | 2017-08-02 | 2019-02-02 | Pharmanutra S P A | Composizione per uso nella prevenzione e nel trattamento di carenza di ferro |
| WO2019237054A1 (en) | 2018-06-08 | 2019-12-12 | Epizon Pharma, Inc. | Methods and compositions for preventing or treating calciphylaxis |
| SG11202012070YA (en) | 2018-06-08 | 2021-01-28 | Epizon Pharma Inc | Methods and compositions for preventing or treating tissue calcification |
| IT201900007326A1 (it) | 2019-05-27 | 2020-11-27 | Alesco Srl | Composizioni comprendenti acidi grassi cetilati e loro uso nel trattamento di artriti e stati infiammatori articolari |
| IT201900007311A1 (it) | 2019-05-27 | 2020-11-27 | Alesco Srl | Procedimento per la preparazione di una composizione comprendente acidi grassi cetilati |
| CN114748486A (zh) * | 2022-03-25 | 2022-07-15 | 南京盛德生物科技研究院有限公司 | 一种含有维生素k2改善心血管钙化的药物组合物及其制备方法与应用 |
| EP4531825A1 (en) | 2022-05-31 | 2025-04-09 | Region Syddanmark | Vitamin k2 for use in treatment of coronary artery calcification |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3860849B2 (ja) * | 1994-04-28 | 2006-12-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗動脈硬化治療剤 |
| EP0831728A2 (en) * | 1995-06-06 | 1998-04-01 | Campbell Soup Company | Mineral supplements for dietetic food |
| US6361800B1 (en) * | 2000-04-13 | 2002-03-26 | Cooper Concepts, Inc. | Multi-vitamin and mineral supplement |
| GB0220182D0 (en) * | 2002-08-30 | 2002-10-09 | Cardiovascular Res Inst Maastr | Organic compounds |
| CA2544235C (en) * | 2003-10-28 | 2013-12-10 | Emory University | Dialysates and methods and systems related thereto |
| US20050281888A1 (en) * | 2004-06-16 | 2005-12-22 | Chandra Ranjit K | Nutritional supplement for infants |
| US20060134226A1 (en) * | 2004-11-16 | 2006-06-22 | Todd Leonard | Compositions useful to treat ocular neovascular diseases and macular degeneration |
| ES2634142T3 (es) * | 2005-12-23 | 2017-09-26 | Ajay Gupta | Composición de nutrición parenteral que contiene hierro |
| CN105055446B (zh) * | 2006-01-30 | 2022-06-03 | 宝龄富锦生技股份有限公司 | 逆转、防止、延迟或稳定软组织钙化的方法 |
| US20100021573A1 (en) * | 2008-07-22 | 2010-01-28 | Michael J Gonzalez | Compositions and methods for the prevention of cardiovascular disease |
| WO2010073642A1 (ja) * | 2008-12-25 | 2010-07-01 | 有限会社 アイ・ビー・イー | 生物活性剤、医薬、化粧品、鮮度保持剤、および植物および動物の発育促進剤 |
| EP2709460A1 (en) * | 2011-05-20 | 2014-03-26 | Friesland Brands B.V. | Composition comprising vitamin k2 |
| ITMI20121350A1 (it) * | 2012-07-31 | 2014-02-01 | Alesco Srl | Composizione solido a base di ferro per uso nelle condizioni di deficienza di ferro. |
| EP2886129A1 (en) * | 2013-12-20 | 2015-06-24 | VitaK B.V. | Prevention and counteraction of diet-induced thrombosis risk |
| US20180199610A1 (en) * | 2015-02-20 | 2018-07-19 | Vitak B.V. | Vitamin k and capillary function |
| US11344575B2 (en) * | 2016-08-15 | 2022-05-31 | Summit Innovation Labs, LLC | Vascular calcification prevention and treatment |
-
2017
- 2017-07-26 IT IT102017000085412A patent/IT201700085412A1/it unknown
-
2018
- 2018-07-26 MA MA049794A patent/MA49794A/fr unknown
- 2018-07-26 EP EP18762623.9A patent/EP3657963A1/en not_active Withdrawn
- 2018-07-26 PE PE2020000102A patent/PE20200794A1/es unknown
- 2018-07-26 JP JP2020502672A patent/JP2020528888A/ja active Pending
- 2018-07-26 MX MX2020000806A patent/MX2020000806A/es unknown
- 2018-07-26 US US16/631,426 patent/US20200206157A1/en not_active Abandoned
- 2018-07-26 WO PCT/IB2018/055586 patent/WO2019021232A1/en not_active Ceased
- 2018-07-26 CN CN201880045110.6A patent/CN111031813A/zh active Pending
- 2018-07-26 EA EA202090069A patent/EA202090069A1/ru unknown
- 2018-07-26 IL IL272138A patent/IL272138B2/en unknown
- 2018-07-26 JO JOP/2020/0012A patent/JOP20200012A1/ar unknown
- 2018-07-26 CA CA3070659A patent/CA3070659A1/en active Pending
- 2018-07-26 KR KR1020207001554A patent/KR20200032691A/ko not_active Ceased
- 2018-07-26 BR BR112020000902-4A patent/BR112020000902B1/pt not_active IP Right Cessation
-
2020
- 2020-01-17 CO CONC2020/0000526A patent/CO2020000526A2/es unknown
- 2020-01-17 PH PH12020550031A patent/PH12020550031A1/en unknown
- 2020-01-20 CL CL2020000170A patent/CL2020000170A1/es unknown
- 2020-01-23 ZA ZA2020/00461A patent/ZA202000461B/en unknown
-
2023
- 2023-05-02 JP JP2023076299A patent/JP2023090869A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528888A5 (enExample) | ||
| JP2023090869A5 (enExample) | ||
| JP5829607B2 (ja) | ω３脂肪酸の配合製剤 | |
| JP2014077003A5 (enExample) | ||
| US20100166918A1 (en) | Nutraceuticals containing nitro fatty acids | |
| JP2016510326A5 (enExample) | ||
| JP2016517851A5 (enExample) | ||
| JP2015522029A5 (enExample) | ||
| JP2016511753A5 (enExample) | ||
| RU2017114933A (ru) | Соединения и композиции для лечения или профилактики патологических состояний, связанных с избыточным отложением фибрина и/или образованием тромбов | |
| IL292262B2 (en) | Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid | |
| JP5788527B2 (ja) | キナーゼ阻害剤の副作用低減剤 | |
| JP2019206562A5 (enExample) | ||
| JP2017523219A5 (enExample) | ||
| RU2015139225A (ru) | Применение производных, содержащих связи с-о-р, у пациентов с почечной недостаточностью | |
| CN105339006A (zh) | 含有脂肪酸和亚硝酸盐的营养或膳食补充剂 | |
| WO2018193648A1 (ja) | アルカリ性化剤による血液浄化 | |
| US9968629B2 (en) | Product and method for supporting uridine homeostasis | |
| JP2018507260A5 (enExample) | ||
| PT1635838E (pt) | Inibidores da fosfodiesterase 5 para a profilaxia e/ou terapia da hipertonia portal | |
| JP2018521031A5 (enExample) | ||
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| JP2009515951A5 (enExample) | ||
| JP2016512243A5 (enExample) | ||
| CA3060154A1 (en) | Blood purification by alkalinizing agent |